Loading
institutionsInstitution
Inselspital, Bern University Hospital / University Cancer Center Inselspital
Bern's university hospital, a high-volume radioligand therapy centre and home to the Bern Center for Precision Medicine and the SAKK trial group.
Also called: InselspitalUCI BernBern Center for Precision Medicine
Overview
The University Cancer Center Inselspital coordinates cancer care at Switzerland's capital university hospital. Its nuclear medicine department under Axel Rominger is one of Europe's largest PSMA and somatostatin-receptor radioligand therapy centres with a strong dosimetry programme, and Mark Rubin, co-discoverer of the TMPRSS2-ERG fusion in prostate cancer, directs the Department for BioMedical Research and the Bern Center for Precision Medicine. The hospital runs neuro-oncology and neurosurgery, thoracic and gastrointestinal surgery, haematology and CAR-T, and is a lead site for the Swiss Group for Clinical Cancer Research (SAKK), whose coordinating centre is in Bern. The Insel Gruppe covers a large catchment across the Bernese region.
Location
Bern, CH
Type
hospital · Universität Bern
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#103 · 38 points (0 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to University Hospital of Bern, including child institutions. 470 works · 4,598 citations · 85% open access · 11% clinical trials · 3% reviews.
Oncology works per year
922022
1072023
862024
1072025
782026
Most works
- Thomas Pabst42 works
- Michael Daskalakis34 works
- Ulrike Bacher34 works
- Urban Novak32 works
- Katja Seipel25 works
- Pauline Aeschbacher19 works
- Martin D. Berger19 works
- Anna S. Wenning16 works
- Beat Gloor15 works
- Gerald Wulf13 works
Most cited
- Radioligand therapy and dosimetry
- Bern Center for Precision Medicine
- Prostate cancer genomics
- Neuro-oncology
- SAKK trials
Adrian Ochsenbein
Director UCI; Chief Physician, Medical Oncology
Medical oncologyLeukaemia stem cellsTumour immunology
Bern medical oncology chief whose lab targets leukaemia stem cells and CD70 signalling.
Daniel M. Aebersold
Chair of the UCI Directorate; Chief Physician, Radiation Oncology
Radiation oncologyHead and neck cancerProstate cancer radiotherapy
Radiation oncologist who chairs the directorate of the University Cancer Center Inselspital in Bern.
Similar pages
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Dosimetry, Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- PersonKen Herrmann
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- PairingPSMA PET → PSMA radioligand therapy
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- CompanyPOINT Biopharma
Shares Somatostatin receptor 2, PSMA, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- TreatmentLocametz (kit for Ga-68 gozetotide)
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- PersonLouise Emmett
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
cancers
fronts
technologies
targets
drugs
ApprovedRadioligand therapy (beta)
Lutetium-177 dotatate · Lutathera
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto